Dozens of deaths among middle-aged Britons have been linked to blockbuster weight loss injections, known as GLP-1 jabs, including popular brands like Ozempic, Mounjaro, and Wegovy. Since the beginning of 2024, drug watchdogs have received 52 fatal reports associated with these injections, contributing to a total of 173 'reports with fatal outcomes' recorded by the Medicines and Healthcare products Regulatory Agency (MHRA) concerning GLP-1 injections.

Experts, including Tam Fry, chair of the National Obesity Forum, have expressed alarm over this death toll. While acknowledging the drugs' effectiveness for those who genuinely need them, Fry warned that these medications are being used 'inappropriately' by slimmer adults seeking to lose a bit of weight. He emphasized the severe complications and even death that can result from misuse, cautioning that many believe it won't happen to them until it does.

The MHRA's data, which does not specify whether the deceased were using the jabs inappropriately, reveals that while two reported deaths were adults in their 20s, the majority occurred among middle-aged individuals: eight in their 30s, 15 in their 40s, and 37 in their 50s. Health chiefs caution that a reported death does not automatically imply causation by the medicine; underlying illnesses, concurrent medications, or coincidental factors like obesity-related conditions (cancer, heart disease) could also be responsible.

Despite these warnings, the drugs' popularity is soaring, with an estimated 1.5 million people in the UK using weight loss jabs through private online pharmacies and another 200,000 via the NHS. This surge has corresponded with a rise in reported side effects, ranging from milder symptoms like headaches, vomiting, and diarrhea, to more serious complications such as gallstones, kidney stones, and inflammation of the pancreas, which some doctors have described as 'life-threatening'.

The investigation highlights specific drugs and their reported fatal links: exenatide (Bydureon) was associated with 55 deaths, semaglutide (Ozempic and Wegovy) with 31, and tirzepatide (Mounjaro) with 38. The MHRA notes that these numbers might be inflated if some cases list multiple GLP-1s as suspected drugs. Furthermore, experts warn that the MHRA's figures might be an 'iceberg tip' due to potential under-reporting, as only an estimated one in ten serious reactions are reported.

A tragic case in point is Susan McGowan, a 58-year-old Scottish nurse whose death in September 2024 was directly linked to a weight-loss jab. She suffered multiple organ failure, septic shock, and pancreatitis after taking two low-dose Mounjaro injections, which she purchased from an online pharmacy. Her death certificate explicitly listed 'the use of prescribed tirzepatide' as a contributing factor.

The MHRA's Yellow Card scheme, established after the thalidomide scandal, allows healthcare professionals and the public to report suspected adverse reactions. This data helps in reviewing drugs, adding warnings, or even removing them from the market. Newly introduced drugs like Ozempic and Mounjaro are also part of the 'Black Triangle' scheme, signifying they require additional monitoring. The Yellow Card scheme has had notable successes, such as identifying a dangerous interaction between warfarin and cranberry juice in 2009 and linking TNF inhibitors to tuberculosis in 2014.

The accessibility of these drugs remains a concern. While NHS prescription guidelines are strict, private online pharmacies facilitate access, enabling individuals to lie about their weight and height. Tam Fry described this situation as 'Pandora's Box has been opened,' advocating that these drugs should only be used by individuals seriously ill with obesity and under strict medical supervision. The trend was partly fueled by celebrity endorsements, with figures like Kim Kardashian and Lottie Moss discussing their use; Lottie Moss notably reported an 'Ozempic overdose' that led to her hospitalization.

Despite the risks, politicians acknowledge the potential benefits. Prime Minister Keir Starmer and Health Secretary Wes Streeting have suggested these medicines could be vital for the economy and health by helping people re-enter the workforce. However, the Department for Health emphasizes that weight loss drugs are not a 'quick fix' but licensed medicines to be used under medical supervision by eligible individuals. Dr. Alison Cave, MHRA Chief Safety Officer, affirmed that the benefits of GLP-1 medicines outweigh potential risks when used for licensed indications, reiterating the importance of reporting suspected side effects via the Yellow Card scheme.

Manufacturers Novo Nordisk (Ozempic, Wegovy) and Eli Lilly and Company (Mounjaro) both stress patient safety as their top priority, continuously monitoring and evaluating safety data. There are also growing concerns about illegal, knock-off versions of these drugs being advertised, particularly on social media. Experts are calling for tighter restrictions on how weight loss drugs are prescribed, advocating for greater control over what is currently, in many instances, an 'uncontrolled drug'.